Immune-Related Genes' Prognostic, Therapeutic and Diagnostic Value in Ovarian Cancer Immune-Related Gene Biomarker in Ovarian Cancer

Overview

Journal Cancer Control

Specialty Oncology

Date 2023 Apr 20

PMID 37078136

Authors

Bo Ding

Wenjing Yan

Siyuan Shen

Dan Meng

Xue Chen

Shizhi Wang

Yang Shen

Affiliations

Soon will be listed here.

Abstract

Objectives: The abnormal expression of immune-related genes (IRGs) plays an important role in the occurrence and progression of ovarian cancer (OC), which is the main cause of mortality among gynecological cancer patients. This study aims to establish a prognostic risk model and comprehensively analyze the relationship between OC risk score and prognosis, immune cell infiltration (ICI) and therapeutic sensitivity in OC.

Methods: We retrospectively evaluated the clinicopathological characteristics of consecutive OC patients in the Cancer Genome Atlas (TCGA) database. First, the prognostic risk model was constructed by bioinformatics methods. And then, we systematically assessed model robustness, and correlations between risk score and prognosis, and immune cell infiltration. The ICGC cohort was used to verify the prognostic risk model. Finally, we evaluated their value in the treatment of OC immunotherapy and chemotherapy.

Results: A total of 10 IRGs were identified to construct the prognostic risk model. Survival analysis revealed that patients in the low-risk group had a better prognosis ( < .01), and the risk score might be considered an independent predictor for predicting the prognosis. In addition, risk scores and patient clinical information were used to construct clinical nomograms, improving the prediction's precision. We also explored the relationship between the risk score and ICI, immunotherapy and drug sensitivity.

Conclusions: Collectively, we identified a novel ten IRGs signature that may be applied as a prognostic predictor of OC, thereby benefiting clinical decision-making and personalized treatment of patients.

Citing Articles

New Achievements from Molecular Biology and Treatment Options for Refractory/Relapsed Ovarian Cancer-A Systematic Review.

Bachmann C Cancers (Basel). 2023; 15(22).

PMID: 38001616 PMC: 10669965. DOI: 10.3390/cancers15225356.

References

Fontana F, Marzagalli M, Raimondi M, Zuco V, Zaffaroni N, Limonta P . δ-Tocotrienol sensitizes and re-sensitizes ovarian cancer cells to cisplatin via induction of G1 phase cell cycle arrest and ROS/MAPK-mediated apoptosis. Cell Prolif. 2021; 54(11):e13111. PMC: 8560608. DOI: 10.1111/cpr.13111. View

Le Saux O, Ray-Coquard I, Intidhar Labidi-Galy S . Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. Semin Cancer Biol. 2020; 77:127-143. DOI: 10.1016/j.semcancer.2020.08.017. View

Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda N . Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun. 2018; 9(1):2724. PMC: 6045647. DOI: 10.1038/s41467-018-05072-0. View

Herbst R, Morgensztern D, Boshoff C . The biology and management of non-small cell lung cancer. Nature. 2018; 553(7689):446-454. DOI: 10.1038/nature25183. View

Izar B, Tirosh I, Stover E, Wakiro I, Cuoco M, Alter I . A single-cell landscape of high-grade serous ovarian cancer. Nat Med. 2020; 26(8):1271-1279. PMC: 7723336. DOI: 10.1038/s41591-020-0926-0. View

Kilgour M, MacPherson S, Zacharias L, Ellis A, Sheldon R, Liu E . 1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer. Sci Adv. 2021; 7(4). PMC: 7817098. DOI: 10.1126/sciadv.abe1174. View

Vazquez-Garcia I, Uhlitz F, Ceglia N, Lim J, Wu M, Mohibullah N . Ovarian cancer mutational processes drive site-specific immune evasion. Nature. 2022; 612(7941):778-786. PMC: 9771812. DOI: 10.1038/s41586-022-05496-1. View

Laios A, OToole S, Flavin R, Martin C, Ring M, Gleeson N . An integrative model for recurrence in ovarian cancer. Mol Cancer. 2008; 7:8. PMC: 2248209. DOI: 10.1186/1476-4598-7-8. View

Moufarrij S, Dandapani M, Arthofer E, Gomez S, Srivastava A, Lopez-Acevedo M . Epigenetic therapy for ovarian cancer: promise and progress. Clin Epigenetics. 2019; 11(1):7. PMC: 6334391. DOI: 10.1186/s13148-018-0602-0. View

10.

Simoni Y, Becht E, Fehlings M, Loh C, Koo S, Teng K . Bystander CD8 T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018; 557(7706):575-579. DOI: 10.1038/s41586-018-0130-2. View

11.

Li X, Liang W, Zhao H, Jin Z, Shi G, Xie W . Immune Cell Infiltration Landscape of Ovarian Cancer to Identify Prognosis and Immunotherapy-Related Genes to Aid Immunotherapy. Front Cell Dev Biol. 2021; 9:749157. PMC: 8595115. DOI: 10.3389/fcell.2021.749157. View

12.

Tsuji T, Matsuzaki J, Odunsi K . Tissue residency of memory CD8 T cells matters in shaping immunogenicity of ovarian cancer. Cancer Cell. 2022; 40(5):452-454. PMC: 11778921. DOI: 10.1016/j.ccell.2022.04.008. View

13.

Sun X, Li S, Lv X, Yan Y, Wei M, He M . Immune-Related Long Non-coding RNA Constructs a Prognostic Signature of Ovarian Cancer. Biol Proced Online. 2021; 23(1):24. PMC: 8903634. DOI: 10.1186/s12575-021-00161-9. View

14.

Xu J, Fang Y, Chen K, Li S, Tang S, Ren Y . Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer. Clin Cancer Res. 2022; 28(16):3590-3602. PMC: 9662915. DOI: 10.1158/1078-0432.CCR-22-0296. View

15.

Zhang M, Cheng S, Jin Y, Zhao Y, Wang Y . Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim Biophys Acta Rev Cancer. 2021; 1875(2):188503. DOI: 10.1016/j.bbcan.2021.188503. View

16.

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

17.

Duska L, Kohn E . The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications. Ann Oncol. 2017; 28(suppl_8):viii8-viii12. PMC: 6246280. DOI: 10.1093/annonc/mdx445. View

18.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

19.

Wan C, Keany M, Dong H, Al-Alem L, Pandya U, Lazo S . Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. Cancer Res. 2020; 81(1):158-173. PMC: 7878408. DOI: 10.1158/0008-5472.CAN-20-1674. View

20.

Scheper W, Kelderman S, Fanchi L, Linnemann C, Bendle G, de Rooij M . Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat Med. 2018; 25(1):89-94. DOI: 10.1038/s41591-018-0266-5. View